Total Payments
$84,766
2024 Payments
$10,656
Companies
24
Transactions
250
Medicare Patients
886
Medicare Billing
$82,490
Payment Breakdown by Category
Other$48,490 (57.2%)
Consulting$13,960 (16.5%)
Travel$10,563 (12.5%)
Research$7,299 (8.6%)
Food & Beverage$4,361 (5.1%)
Education$93.11 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $48,050 | 25 | 56.7% |
| Consulting Fee | $13,960 | 4 | 16.5% |
| Travel and Lodging | $10,563 | 32 | 12.5% |
| Unspecified | $7,299 | 12 | 8.6% |
| Food and Beverage | $4,361 | 172 | 5.1% |
| Honoraria | $440.00 | 1 | 0.5% |
| Education | $93.11 | 4 | 0.1% |
Payments by Type
General
$77,467
238 transactions
Research
$7,299
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $74,851 | 138 | $0 (2024) |
| Merck Sharp & Dohme LLC | $7,369 | 16 | $0 (2022) |
| Intercept Pharmaceuticals, Inc. | $577.34 | 11 | $0 (2021) |
| ABBVIE INC. | $365.03 | 23 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $285.69 | 5 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $272.06 | 13 | $0 (2024) |
| Janssen Biotech, Inc. | $138.23 | 7 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $123.21 | 5 | $0 (2022) |
| VIVUS, Inc. | $103.58 | 5 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $96.48 | 5 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,656 | 20 | Gilead Sciences, Inc. ($10,564) |
| 2023 | $164.23 | 8 | Mallinckrodt Hospital Products Inc. ($71.86) |
| 2022 | $388.08 | 17 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($119.89) |
| 2021 | $2,225 | 5 | Gilead Sciences, Inc. ($1,750) |
| 2020 | $6,889 | 18 | Gilead Sciences, Inc. ($6,774) |
| 2019 | $18,603 | 53 | Gilead Sciences, Inc. ($18,081) |
| 2018 | $26,913 | 73 | Gilead Sciences, Inc. ($19,073) |
| 2017 | $18,927 | 56 | Gilead Sciences Inc ($18,470) |
All Payment Transactions
250 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.72 | General |
| 09/17/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,370.00 | General |
| 07/24/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: Rare Disease | ||||||
| 07/03/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Gastroenterology | ||||||
| 07/02/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,190.00 | General |
| 06/21/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $171.29 | General |
| 06/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.52 | General |
| 06/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.57 | General |
| 06/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $9.75 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $818.65 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $723.79 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $95.22 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $59.81 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.37 | General |
| 06/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.82 | General |
| 05/09/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: IMMUNOLOGY | ||||||
| 04/19/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $30.19 | General |
| Category: Immunology | ||||||
| 04/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.10 | General |
| 02/14/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.25 | General |
| 01/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.73 | General |
| 09/21/2023 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $24.21 | General |
| Category: CRITICAL CARE | ||||||
| 09/13/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.51 | General |
| 08/10/2023 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: CRITICAL CARE | ||||||
| 08/07/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.49 | General |
| 06/07/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: Gastroenterology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and,or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial | Merck Sharp & Dohme Corporation | $6,599 | 9 |
| A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B Grazoprevir,Ruzasvir,Uprifosbuvir in Participants with Chronic Hepatitis C Virus Genotype 3 Infection | Merck Sharp & Dohme Corporation | $300.00 | 1 |
| A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682C Ruzasvir,Uprifosbuvir in Participants with Chronic Hepatitis C Virus Genotype 1 or 4 Infection | Merck Sharp & Dohme Corporation | $200.00 | 1 |
| MK-3682C Ruzasvir,Uprifosbuvir in HCV GT2 | Merck Sharp & Dohme Corporation | $200.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 125 | 211 | $35,293 | $13,857 |
| 2022 | 7 | 245 | 390 | $66,875 | $25,937 |
| 2021 | 7 | 268 | 399 | $61,650 | $25,001 |
| 2020 | 6 | 248 | 350 | $49,589 | $17,695 |
Total Patients
886
Total Services
1,350
Medicare Billing
$82,490
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 69 | 99 | $15,642 | $6,526 | 41.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 76 | $12,540 | $4,723 | 37.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 19 | $5,377 | $1,944 | 36.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 17 | $1,734 | $665.38 | 38.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 67 | 96 | $15,168 | $6,877 | 45.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 28 | 114 | $18,810 | $6,341 | 33.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 54 | 73 | $11,534 | $5,021 | 43.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 27 | 37 | $10,471 | $3,824 | 36.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 17 | 17 | $4,556 | $1,709 | 37.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $3,752 | $1,284 | 34.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 11 | 11 | $1,100 | $526.18 | 47.8% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 15 | 16 | $1,040 | $253.88 | 24.4% |
| 91200 | Measurement of liver stiffness | Facility | 2022 | 12 | 12 | $444.00 | $100.04 | 22.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 53 | 74 | $11,692 | $5,541 | 47.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 89 | $14,685 | $5,090 | 34.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 52 | 69 | $10,902 | $4,941 | 45.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 22 | 27 | $7,641 | $2,925 | 38.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 20 | 20 | $5,360 | $2,079 | 38.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 16 | 16 | $4,288 | $1,751 | 40.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 22 | 30 | $3,000 | $1,363 | 45.4% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 38 | 48 | $3,120 | $1,096 | 35.1% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 14 | 14 | $518.00 | $114.92 | 22.2% |
| 91200 | Measuring the stiffness in the liver via elastography | Facility | 2021 | 12 | 12 | $444.00 | $101.75 | 22.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 35 | 113 | $18,645 | $6,249 | 33.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 31 | 39 | $11,037 | $4,319 | 39.1% |
About Dr. Anthony Post, MD
Dr. Anthony Post, MD is a Gastroenterology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710907357.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Post, MD has received a total of $84,766 in payments from pharmaceutical and medical device companies, with $10,656 received in 2024. These payments were reported across 250 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($48,050).
As a Medicare-enrolled provider, Post has provided services to 886 Medicare beneficiaries, totaling 1,350 services with total Medicare billing of $82,490. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Cleveland, OH
- Active Since 07/19/2006
- Last Updated 01/14/2021
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1710907357
Products in Payments
- Epclusa (Drug) $43,057
- MK-5172 (Drug) $6,599
- Vosevi (Drug) $4,898
- OCALIVA (Drug) $523.35
- MK-3682C (Drug) $400.00
- MK-3682B (Drug) $300.00
- Kanuma (Drug) $285.69
- XIFAXAN (Drug) $223.42
- STELARA (Biological) $138.23
- Humira (Biological) $127.69
- OPDIVO (Biological) $123.21
- PANCREAZE (Drug) $103.58
- Nexavar (Drug) $95.27
- Mavyret (Drug) $84.30
- Cimzia (Drug) $75.67
- GIAPREZA (Drug) $75.00
- Entyvio (Biological) $73.86
- TERLIVAZ (Drug) $71.86
- XIFAXANIBSD (Drug) $61.34
- Lenvima (Drug) $57.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Cleveland
Pierre Gholam, Md, MD
Gastroenterology — Payments: $1.7M
Gastroenterology $1.7M
Ronnie Fass, Md, MD
Gastroenterology — Payments: $308,587
Gastroenterology $308,587
Dr. Taha Qazi, M.d, M.D
Gastroenterology — Payments: $185,665
Gastroenterology $185,665
Dr. Benjamin Cohen, Md, MD
Gastroenterology — Payments: $140,217
Gastroenterology $140,217
Amandeep Singh, Mbbs, MBBS
Gastroenterology — Payments: $111,838
Gastroenterology $111,838
Bo Shen, Md, MD
Gastroenterology — Payments: $103,946
Gastroenterology $103,946